{
    "clinical_study": {
        "@rank": "166353", 
        "acronym": "SUMMIT", 
        "arm_group": [
            {
                "arm_group_label": "SLITone ULTRA low dose", 
                "arm_group_type": "Active Comparator", 
                "description": "SLITone ULTRA HDM immunotherapy"
            }, 
            {
                "arm_group_label": "SLITone ULTRA medium dose", 
                "arm_group_type": "Active Comparator", 
                "description": "SLITone ULTRA HDM immunotherapy"
            }, 
            {
                "arm_group_label": "SLITone ULTRA high dose", 
                "arm_group_type": "Active Comparator", 
                "description": "SLITone ULTRA HDM immunotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the trial is to evaluate the dose-response relationship with\n      regards to change in immunological parameters and safety for SLITone ULTRA house dust mite\n      mix in adult subjects with moderate to severe HDM allergic rhinitis."
        }, 
        "brief_title": "A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 18 or older\n\n          -  Moderate to severe persistent HDM allergic rhinitis with or without asthma\n\n          -  Moderate to severe HDM allergic rhinitis symptoms during a baseline period\n\n          -  Positive skin prick test response (wheal diameter \u2265 3 mm)\n\n          -  Positive specific IgE \u2265 IgE Class 2, \u2265 0.70 kU/l)\n\n        Exclusion Criteria:\n\n          -  Previous treatment with immunotherapy with House dust mite immunotherapy\n\n          -  Ongoing treatment with any allergen specific immunotherapy product\n\n          -  Reduced lung function\n\n          -  Clinical history of uncontrolled asthma\n\n          -  Inflammatory conditions in the oral cavity with severe symptoms\n\n          -  History of anaphylaxis with cardiorespiratory symptoms\n\n          -  History of recurrent generalised urticaria\n\n          -  A history of drug induced  facial angioedema or hereditary angiooedema\n\n          -  Any clinically relevant chronic disease (\u22653 months duration)\n\n          -  Systemic disease affecting the immune system\n\n          -  Immunosuppressive treatment\n\n          -  Currently treated with tricyclic antidepressants; catecholamine-Methyltransferase\n             inhibitors and mono amine oxidase inhibitors"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "219", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728298", 
            "org_study_id": "SU-M-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "SLITone ULTRA low dose", 
                "SLITone ULTRA medium dose", 
                "SLITone ULTRA high dose"
            ], 
            "intervention_name": "SLITone ULTRA HDM immunotherapy", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "House Dust Mite", 
            "allergy", 
            "rhinitis", 
            "asthma"
        ], 
        "lastchanged_date": "January 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toulouse", 
                    "country": "France", 
                    "zip": "31059"
                }, 
                "name": "Proffesor Alain Didier"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy - The SUMMIT Trial", 
        "overall_official": {
            "affiliation": "H\u00f4pital Larrey, Toulouse", 
            "last_name": "Alain Didier, Pr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in IgE-blocking factor after 6 months of treatment", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728298"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of subjects with treatment related adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "ALK-Abell\u00f3 A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ALK-Abell\u00f3 A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}